Lung cancer: Update on the treatment of small cell lung cancer (SCLC)
Open Access
- 1 September 2000
- journal article
- review article
- Published by Elsevier in Annals of Oncology
- Vol. 11 (suppl_3) , 101-110
- https://doi.org/10.1093/annonc/11.suppl_3.101
Abstract
No abstract availableThis publication has 53 references indexed in Scilit:
- Phase II Study of Oral Platinum Drug JM216 as First-Line Treatment in Patients With Small-Cell Lung CancerJournal of Clinical Oncology, 1999
- Cisplatin, Etoposide, and Paclitaxel in the Treatment of Patients With Extensive Small-Cell Lung CarcinomaJournal of Clinical Oncology, 1999
- Five-Day Oral Etoposide2 Treatment for Advanced Small-Cell Lung Cancer: Randomized Comparison With Intravenous ChemotherapyJNCI Journal of the National Cancer Institute, 1997
- Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trialThe Lancet, 1996
- Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinomaCancer, 1996
- Phase II study of docetaxel (taxotere) in patients with previously untreated extensive small cell lung cancerInvestigational New Drugs, 1995
- Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study.Journal of Clinical Oncology, 1995
- Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study.Journal of Clinical Oncology, 1995
- Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC)Annals of Oncology, 1994
- Initial Chemotherapeutic Doses and Survival in Patients with Limited Small-Cell Lung CancerNew England Journal of Medicine, 1993